Agarophyton chilensis extract, enriched with free fatty acids and PPARγ modulators, comprising palmitic acid, stearic acid, myristic acid, oleic acid, and 8-hydroxyeicosatetraenoic acid (8-HETE). Method for obtaining the extract. Nutraceutical composition, comprising the extract enriched with free fatty acids and PPARγ modulators, wherein said extract is useful for treating or preventing health problems, which require neuroprotection, wherein said neuroprotection involves activation of PPARγ receptors.

Agarophyton chilensis extract, enriched with free fatty acids and PPARγ modulators, comprising palmitic acid, stearic acid, myristic acid, oleic acid, and 8-hydroxyeicosatetraenoic acid (8-HETE). Method for obtaining the extract. Nutraceutical composition, comprising the extract enriched with free fatty acids and PPARγ modulators, wherein said extract is useful for treating or preventing health problems, which require neuroprotection, wherein said neuroprotection involves activation of PPARγ receptors.

Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation. This agent includes at least one extract selected from among a group consisting of brown algae, red algae and green algae.

Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation. This agent includes at least one extract selected from among a group consisting of brown algae, red algae and green algae.

The present invention relates to griffithsin polypeptides and methods of using the same in inhibition of viral infection. Certain embodiments of the present invention relate to modified griffithsin polypeptides and methods of inhibiting coronavirus infection in a host by administering modified griffithsin polypeptides to the upper respiratory tract of the host. Further embodiments relate to an intranasal spray formulation including griffithsin polypeptides in a composition including a preservative and a viscosity modifier.

The purpose of this invention is to provide a method with which it is easy to perform screening for an agent that proliferates or an agent that minimizes the reduction in MCSP-positive basal epidermal stem cells. Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation, said agent including at least one extract selected from among a group consisting of brown algae, red algae and green algae.

The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.

The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.

The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.

The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely λ carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, pseudoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.